When Fitbit announced, after months of hints and rumors, that it was launching a smartwatch, it seemed likely that the answer to one big question would determine whether the health and fitness company could succeed: Could Fitbit build an app store to compete with the Apple Watch's?
Now, the app store in question, Fitbit's App Gallery, is finally starting to take shape. Fitbit announced today that...
Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some time assuaging investor fears about that friction.
“Late in the third quarter, the FDA approved Abbott's FreeStyle Libre flash glucose monitoring system,” Sayer said on the call. “We always believed the...
All of the diverse operations of Verily, the life sciences technology company that began its life as Google X Life Sciences, can be summed up with a simple sentence: We should be treating our bodies at least as well as we treat our cars.
At the Health 2.0 Fall Conference in Santa Clara this week, Verily Chief Technology Officer Brian Otis spoke with Health 2.0 cofounder and CEO Dr. Indu Subaya on...
Continuous glucose monitoring company Dexcom, which already allows users to monitor their CGM data on their phones and Apple Watch, is now making some patient data available to third parties via an API.
"If you look back at the past when our hardware was all proprietary, we’ve evolved from that to an app company where our CGM now works as an app on the phone," Dexcom CEO Kevin Sayer told...
Good news for anyone who thought Fitbit's move toward the smartwatch market would be a move away from health: The wearable maker has just announced a partnership with Dexcom that will bring data from the company's continuous glucose monitor directly to the display of Fitbit's upcoming Ionic smartwatch.
Athough Fitbit's have been used in the management of chronic diseases in a number of hospital...
A new study published today in Annals of Internal Medicine and sponsored by Dexcom shows that a continuous glucose monitor could lower the HbA1c scores of people with Type 2 diabetes, and that acceptance of the technology is high among that group as well.
Right now, continuous glucose monitoring is a technology mostly used by people with Type 1 diabetes, many of whom administer insulin via an...
Touchscreen insulin pump maker Tandem Diabetes announced a new clinical trial for an insulin pump with a predictive low glucose suspend (PLGS) algorithm. Another step on the road to an artificial pancreas, PLGS allows Tandem to automatically suspend insulin delivery when it predicts low glucose and resume it when glucose starts to rise again.
“The start of this pivotal trial is another important...
GlaxoSmithKline has made a hire signaling its commitment to digital health. Karenann Terrell, former Chief Information Officer at Walmart, will start at GSK in the newly created role of Chief Digital and Technology Officer.
“The impact of technology on the healthcare industry is accelerating and requires us to rethink our approach,” CEO Emma Walmsley said in a statement. “As a member of the...
DexCom hasn’t been shy about its plan for opening up the CGM market by encouraging CGM use in a wider group of people with diabetes — including, eventually, people with Type 2 diabetes. On its second quarter earnings call, the company went deep on that focus on the future.
“More and more people with diabetes are adopting CGM that as the primary tool to manage their condition, especially as we...
It was good news for Dexcom in January when the Centers for Medicare and Medicaid Services announced they would reimburse for Dexcom’s — and initially only Dexcom’s — continuous glucose monitor. Now the rollouts to Medicare patients are starting, although the company isn’t exactly rolling in that government money. In fact, CEO Kevin Sayer said on a recent earnings call that they’ve yet to see a...
